Page last updated: 2024-08-21

pyrazines and cabozantinib

pyrazines has been researched along with cabozantinib in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES	1
El-Shentenawy, A; Mohammed, AA	1
Fang, D; Hu, P; Ni, L; Xu, J; Xu, Z	1
Adeniran, A; Alva, A; Balzer-Haas, N; Bjarnason, GA; Cole, S; George, DJ; Heng, DYC; Humphrey, P; Lara, PN; Narayan, V; Pal, SK; Plets, M; Shuch, B; Stein, M; Tangen, C; Thompson, IM; Tretiakova, M; Vaishampayan, U; Wright, J; Zhang, T	1

Reviews

2 review(s) available for pyrazines and cabozantinib

Article	Year
Novel molecular targeted therapies for refractory thyroid cancer. Head & neck, 2012, Volume: 34, Issue:5 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat	2012
Advanced thyroid cancers: new era of treatment. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:7 Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; ErbB Receptors; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lithium; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Stilbenes; Thalidomide; Thyroid Neoplasms	2014

Article

Year

Novel molecular targeted therapies for refractory thyroid cancer.

Head & neck, 2012, Volume: 34, Issue:5

Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat

2012

Advanced thyroid cancers: new era of treatment.

Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:7

Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; ErbB Receptors; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lithium; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Stilbenes; Thalidomide; Thyroid Neoplasms

2014

Trials

1 trial(s) available for pyrazines and cabozantinib

Article	Year
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet (London, England), 2021, 02-20, Volume: 397, Issue:10275 Topics: Aged; Anilides; Canada; Carcinoma, Renal Cell; Crizotinib; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyridines; Sunitinib; Triazines; United States	2021

Article

Year

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.

Lancet (London, England), 2021, 02-20, Volume: 397, Issue:10275

Topics: Aged; Anilides; Canada; Carcinoma, Renal Cell; Crizotinib; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyridines; Sunitinib; Triazines; United States

2021

Other Studies

1 other study(ies) available for pyrazines and cabozantinib

Article	Year
Electrostatic explanation of D1228V/H/N-induced c-Met resistance and sensitivity to type I and type II kinase inhibitors in targeted gastric cancer therapy. Journal of molecular modeling, 2019, Jan-03, Volume: 25, Issue:1 Topics: Anilides; Binding Sites; Drug Resistance, Neoplasm; Humans; Molecular Dynamics Simulation; Molecular Structure; Molecular Targeted Therapy; Mutation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyridines; Static Electricity; Stomach Neoplasms; Triazines	2019

Article

Year

Electrostatic explanation of D1228V/H/N-induced c-Met resistance and sensitivity to type I and type II kinase inhibitors in targeted gastric cancer therapy.

Journal of molecular modeling, 2019, Jan-03, Volume: 25, Issue:1

Topics: Anilides; Binding Sites; Drug Resistance, Neoplasm; Humans; Molecular Dynamics Simulation; Molecular Structure; Molecular Targeted Therapy; Mutation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyridines; Static Electricity; Stomach Neoplasms; Triazines

2019